Company Makes Rapid Testing Solutions Available to Remote Areas of Colombia and Several Other New Countries
HALIFAX, Feb. 5, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) and its Multiplo™ Rapid TP/HIV rapid test for syphilis and HIV have enabled the success of a humanitarian project led by the Colombian National Navy. Multiplo™ Rapid TP/HIV Antibody Test was used in a project to save the lives of unborn babies in remote areas of Colombia. This is just one example, among many of MedMira's expansion into Latin America and the company's growing customer base in this market. The company has recently earned several key product approvals, established new distribution agreements and made shipments of its products built on its patented and versatile Rapid Vertical Flow Technology™. This technology makes high quality, cost-effective rapid testing solutions possible, in even the most remote locations.
As part of its ongoing humanitarian efforts, the Colombian National Navy has implemented a new program called Expectant Family, which promotes the testing of sexually transmitted diseases in pregnant women living in remote areas where access to healthcare and laboratory testing is limited. The National Navy is using MedMira's Multiplo TP/HIV test to screen women at least twice during the pregnancy, before the third month and prior to giving birth, for syphilis and HIV.
"In the remote areas of Columbia where healthcare services and laboratory testing is scarce, pregnant women do not have access to life saving tests that could easily prevent mother-to-child transmission and neonatal deaths," said Dr. Liliana Lora Sierra, Public Health Support Professional, Colombian National Navy. "Working with MedMira, we are able to offer these women high quality, rapid tests that will help prevent vertical transmission of TP/HIV that could not only save their lives but the lives of their unborn children. The test is very easy to perform and does not require any special training allowing us to screen patients at the point-of-care. Without MedMira's innovative technology, these women would not have access to tests that those living in urban areas benefit from."
In addition to the work in Columbia, MedMira has signed a distribution deal in Venezuela for the Company's Reveal® Rapid HIV Antibody Test. The deal is to provide tests to the private healthcare sector, which serves more than half of all patients and last week the company made the initial shipment to its partners in Venezuela. MedMira has also received approval to market the Reveal HIV test in Costa Rica and has registrations and evaluations for both Reveal and Multiplo product ranges underway in other Latin American countries including Panama, Mexico, Ecuador, Brazil and Argentina. The company continues to leverage its partnership with the Pan American Health Organization (PAHO) having recently received new orders from the National HIV & TB program for the Ministry of Health in Belize.
The company has steadily increased its shipments to Latin America, over the last 12 months, due to the rising demand for cost effective, fast and of high quality products. In addition, the global need for tests that can simultaneously detect multiple markers has highlighted one of the key advantages of MedMira's patented Vertical Flow Technologyä against its competitors, which is the ability to multiplex assays on one device. This enables MedMira to reach a much broader market by attracting partners and customers in the private healthcare, research, and life sciences sectors.
MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information: